STXS Stock Overview
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.88|
|52 Week High||US$7.22|
|52 Week Low||US$1.72|
|1 Month Change||-7.84%|
|3 Month Change||-1.57%|
|1 Year Change||-65.57%|
|3 Year Change||-37.12%|
|5 Year Change||79.05%|
|Change since IPO||-97.60%|
Recent News & Updates
|STXS||US Medical Equipment||US Market|
Return vs Industry: STXS underperformed the US Medical Equipment industry which returned -27.3% over the past year.
Return vs Market: STXS underperformed the US Market which returned -20% over the past year.
|STXS Average Weekly Movement||10.7%|
|Medical Equipment Industry Average Movement||8.5%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: STXS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: STXS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room.
Stereotaxis Fundamentals Summary
|STXS fundamental statistics|
Is STXS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|STXS income statement (TTM)|
|Cost of Revenue||US$10.26m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.25|
|Net Profit Margin||-60.70%|
How did STXS perform over the long term?See historical performance and comparison
Is STXS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for STXS?
Other financial metrics that can be useful for relative valuation.
|What is STXS's n/a Ratio?|
Price to Sales Ratio vs Peers
How does STXS's PS Ratio compare to its peers?
|STXS PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
TCMD Tactile Systems Technology
AXDX Accelerate Diagnostics
KRMD KORU Medical Systems
Price-To-Sales vs Peers: STXS is good value based on its Price-To-Sales Ratio (4.6x) compared to the peer average (4.6x).
Price to Earnings Ratio vs Industry
How does STXS's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: STXS is expensive based on its Price-To-Sales Ratio (4.6x) compared to the US Medical Equipment industry average (3.8x)
Price to Sales Ratio vs Fair Ratio
What is STXS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||4.6x|
|Fair PS Ratio||6.2x|
Price-To-Sales vs Fair Ratio: STXS is good value based on its Price-To-Sales Ratio (4.6x) compared to the estimated Fair Price-To-Sales Ratio (6.2x).
Share Price vs Fair Value
What is the Fair Price of STXS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate STXS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate STXS's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Stereotaxis forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: STXS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: STXS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: STXS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: STXS's revenue (29.2% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: STXS's revenue (29.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if STXS's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Stereotaxis performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: STXS is currently unprofitable.
Growing Profit Margin: STXS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: STXS is unprofitable, and losses have increased over the past 5 years at a rate of 26.1% per year.
Accelerating Growth: Unable to compare STXS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STXS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).
Return on Equity
High ROE: STXS has a negative Return on Equity (-48.39%), as it is currently unprofitable.
Discover strong past performing companies
How is Stereotaxis's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: STXS's short term assets ($46.6M) exceed its short term liabilities ($13.7M).
Long Term Liabilities: STXS's short term assets ($46.6M) exceed its long term liabilities ($7.5M).
Debt to Equity History and Analysis
Debt Level: STXS is debt free.
Reducing Debt: STXS had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: STXS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: STXS has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 0% each year
Discover healthy companies
What is Stereotaxis's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Stereotaxis Dividend Yield vs Market|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.5%|
|Industry Average (Medical Equipment)||1.8%|
|Analyst forecast in 3 Years (Stereotaxis)||n/a|
Notable Dividend: Unable to evaluate STXS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate STXS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if STXS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if STXS's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as STXS has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Fischel (35 yo)
Dr. David Leo Fischel, CPA, CFA, CAIA, MBA, has been the Chairman and Chief Executive Officer of Stereotaxis, Inc. since February 3, 2017 and its Director since September 29, 2016. Dr. Fischel is a Princip...
CEO Compensation Analysis
|David Fischel's Compensation vs Stereotaxis Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$57m||US$60k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$321k||US$5k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$240k||n/a|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$59k||n/a|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$43k||n/a|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||US$28k||n/a|
Compensation vs Market: David's total compensation ($USD57.46M) is above average for companies of similar size in the US market ($USD772.75K).
Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.
Experienced Management: STXS's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: STXS's board of directors are considered experienced (6.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|26 May 22||BuyUS$25,967||Arbiter Partners Capital Management, LLC||Company||14,300||US$1.85|
|24 May 22||BuyUS$25,984||Arbiter Partners Capital Management, LLC||Company||14,292||US$1.86|
|20 May 22||BuyUS$77,725||Arbiter Partners Capital Management, LLC||Company||43,263||US$1.80|
|18 May 22||BuyUS$100,051||Arbiter Partners Capital Management, LLC||Company||55,025||US$1.82|
|13 May 22||BuyUS$287,082||Arbiter Partners Capital Management, LLC||Company||156,751||US$1.88|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Stereotaxis, Inc.'s employee growth, exchange listings and data sources
- Name: Stereotaxis, Inc.
- Ticker: STXS
- Exchange: NYSEAM
- Founded: 1990
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$140.605m
- Shares outstanding: 74.79m
- Website: https://www.stereotaxis.com
Number of Employees
- Stereotaxis, Inc.
- 710 North Tucker Boulevard
- Suite 110
- Saint Louis
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|STXS||NYSEAM (NYSE MKT LLC)||Yes||Common Shares||US||USD||Aug 2004|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/04 00:00|
|End of Day Share Price||2022/10/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.